Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, place…
W Kern, T Wehrhahn, C Le Roux, A Astrup, K Fujioka, F Greenway, D Lau, L Van Gaal, R Violante Ortiz, J Wilding, X Pi-Sunyer, T Skjøth, L Shapiro Manning · Diabetologie und Stoffwechsel · 2016 · Heft 04
Bibliografische Angaben
Zusammenfassung
This 3-year trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet and exercise (D&E), in delaying the onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities. Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo; all were advised on D&E. Efficacy data are observed means, with last observation carried forward for missing values. Of 2254 randomised individuals (n = 2254) with prediabetes (age 47.5 ± 11.7 years, 76.0% female, weight 107.6 ± 21.6 kg, BMI 38.8 ± 6.4 kg/m2, mean ± SD),…
